64 filings
8-K
IVVD
Invivyd, Inc.
23 Sep 24
Other Events
7:07am
8-K
IVVD
Invivyd, Inc.
6 Sep 24
Other Events
9:05am
8-K
IVVD
Invivyd, Inc.
4 Sep 24
Other Events
7:10am
8-K
IVVD
Invivyd, Inc.
3 Sep 24
Center for Disease Control reports KP.3.1.1 is the only major variant increasing in proportionality nationally
7:07am
8-K
IVVD
Invivyd, Inc.
27 Aug 24
Other Events
8:05am
8-K
rba5a mpxj7ies
14 Aug 24
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
8:20am
8-K
ktkxl32gq aiji
14 Jun 24
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
7:07am
8-K
pbofb3xr 8yxnqner0
31 May 24
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
7:12am
8-K
ok05yy2vgi55a yk
22 May 24
Invivyd Elects Two New Independent Members to its Board of Directors
7:06am
8-K
3jpy4d
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
8-K
08b3i8 uojz2wfe
7 May 24
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19
7:38am
8-K
e281dmmwosr62oxs1uf
12 Apr 24
Invivyd Announces CEO Transition
7:36am
8-K
64hiemzymw kzv
4 Apr 24
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
5:25pm
8-K
tvlyl5rkzfjbt 3mos
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
8-K
c4h2735dfj6va ghr6os
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDAâ„¢ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
8-K
snsvcr ih
9 Feb 24
Index to Consolidated Financial Statements
4:01pm
8-K
otz5jrni0mnw jt
8 Jan 24
Other Events
7:12am
8-K
5zuzbfh g1
3 Jan 24
Other Events
7:06am
8-K
eed6foz8avvm 1hprf
22 Dec 23
Entry into a Material Definitive Agreement
4:53pm
8-K
zf6zr
18 Dec 23
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial
7:16am